|
|
Updates in the Diagnosis and Management of Chronic Lymphocytic Leukemia: Strategies for Addressing Disparities in Patient Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Advances in chronic lymphocytic leukemia (CLL) testing and therapy have redefined the standard of care in recent years, prompting updates to current guideline recommendations. At the same time, findings from ongoing clinical trials continue to inform treatment options and de... |
|
|
Refining Management of Classical Hodgkin Lymphoma: What’s on the Horizon for Pediatric Management and AYA Survivorship
Target Audience
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, hematologic oncologists, medical oncologists, hematopathologists, primary care providers, family practitioner internists, hematology/oncology nurses and nurse navigators, nurse practitioners, physician assistants, and pharmacists.
Program Overview
New treatments are poised to expand the armamentarium for pediatric classical Hodgkin lymphoma (cHL). Given the... |
|
|
Advances in Bispecific Antibodies for B-Cell Non-Hodgkin Lymphoma: Rapid Response From New Orleans
Non-Hodgkin lymphoma (NHL) is the most common type of lymphoma, of which B-cell lymphomas (eg, diffuse large B-cell lymphoma [DLBCL], follicular lymphoma [FL], and mantle cell lymphoma [MCL]) are some of the most common subtypes. Historically, first-line treatment is most commonly rituximab plus chemotherapy with or without radiation therapy. With treatment advances, more patients are eligible for newer first-line treatment options such as immunotherapy, targeted therapy, and CAR T-cell therap... |
|
|
On Topic Virtual Roundtable: “BTK Battle” " Experts Compare and Contrast the Latest Data of BTK Inhibitors for the Treatment of Hematologic Malignancies
Program Overview
This online roundtable discussion will focus on the use of BTK in patients with CLL/SLL, lymphoma, and other hematologic malignancies, as well as expert guidance in the selection and sequencing of this class of agents safely and effectively.
Target Audience
The target audience for this activity is community and academic medical oncologists, pulmonologists, allied health professionals, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hema... |
|
|
A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion f... |
|
|
On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma
Program Overview
On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma aims to provide clinical data regarding current and emerging therapeutic BCMA-directed treatment strategies via a panel of experts treating patients with multiple myeloma.
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and ot... |
|
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|
|
Applying Guidelines and Latest Evidence to the Management of Moderate‐to‐Severe Asthma in Children and Adults
Target Audience
The educational design of this activity addresses the needs of pulmonologists, allergists/immunologists, NPs and PAs, and other clinicians involved in the management of patients with moderate‐to‐severe asthma.
Program Overview
Patients with asthma and underlying comorbidities require personalized treatment to achieve asthma control. Children with asthma have an especially high burden of symptoms, and are at risk of impaired lung development if asthma control cannot be ... |
|